Syndax Pharmaceuticals SNDX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $217.42M+26.0% | $172.6M+54.7% | $111.55M+42.7% | $78.18M+78.8% | $43.72M+84.6% | ||
| $255.99M-1.1% | $258.78M+5.3% | $245.67M-5.6% | $260.36M+5.5% | $246.79M+2.1% | ||
| —— | $179.68M+8.9% | $164.98M+9.8% | $150.28M+10.8% | $135.58M+12.2% | ||
| —— | —— | —— | —— | —— | ||
| $440.95M-1.1% | $445.68M+6.5% | $418.45M+0.3% | $417.23M+7.6% | $387.64M+6.7% | ||
| -$223.53M+18.1% | -$273.08M+11.0% | -$306.9M+9.5% | -$339.05M+1.4% | -$343.92M-1.2% | ||
| -102.8%+55.4pp | -158.2%+117pp | -275.1%+159pp | -433.7%+353pp | -786.6%+648pp | ||
| $4K-33.3% | $6K+105% | -$118K-24.2% | -$95K-75.9% | -$54K-5,300% | ||
| -$19.72M-59.8% | -$12.34M-164% | -$4.68M-215% | $4.06M-68.0% | $12.71M-39.2% | ||
| —— | —— | —— | —— | —— | ||
| -$243.25M+14.8% | -$285.42M+8.4% | -$311.58M+7.0% | -$334.99M-1.1% | -$331.2M-3.9% | ||
| -111.9%+53.5pp | -165.4%+114pp | -279.3%+149pp | -428.5%+329pp | -757.5%+589pp | ||
| -$2.79+15.2% | -$3.29+8.6% | -$3.60+7.2% | -$3.88-0.8% | -$3.85-3.5% | ||
| -$223.53M+18.1% | -$273.08M+11.0% | -$306.9M+9.5% | -$339.05M+1.4% | -$343.92M-1.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Syndax Pharmaceuticals's income statement data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.